![Joseph Woodard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joseph Woodard
Keine laufenden Positionen mehr
Vermögen: 4 142 $ am 31.08.2026
Profil
Joseph Paul Woodard formerly worked at Bellicum Pharmaceuticals, Inc., as Senior Vice President-Clinical & Medical Affairs in 2019, Imugene Ltd., as Chief Medical Officer from 2023 to 2025, and Immune-Onc Therapeutics, Inc., as Chief Medical Officer & Senior Vice President.
Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and doctorate degree from UNC School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMUGENE LTD 0,02 % | 30.06.2025 | 85.007 ( 0,02 % ) | 4 142 $ | 31.08.2026 |
Ehemalige bekannte Positionen von Joseph Woodard
| Unternehmen | Position | Ende |
|---|---|---|
| IMUGENE LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 30.05.2025 |
| BELLICUM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2019 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Joseph Woodard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
29
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Imugene Ltd.
 Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UNC School of Medicine
 UNC School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
